Flu bouncing back after Christmas mixing, says NHS

Hospital admissions for flu in England rose to an average of 2,924 last week, a 9% increase week-on-week after two weeks of decline and still well below last winter's peak above 5,000. NHS leaders attribute the bounce to post-Christmas mixing and a cold snap alongside simultaneous rises in Covid and norovirus, reporting more injuries from slips and falls and chronic bed shortages that have normalised corridor care and prompted warnings of deaths and unsustainable operational pressure despite some improvement in ambulance handovers versus last Christmas.

Analysis

Market structure: Short, sharp bounce in flu/norovirus raises near-term demand for diagnostics, bed-capacity providers, temp clinical staffing and private elective capacity. Private hospital operators (HCA, RHC, SPI.L) and diagnostics firms (ABT, RHHBY) see higher revenue per quarter if hospitalisations rise >20% WoW; municipal/public-pay budgets and elective scheduling are the losers, pressuring NHS margins and increasing referral flow to private sector within 1–6 months.

Risk assessment: Tail risks include a severe winter wave (hospitalisations >5,000/week in England) triggering emergency policy (price caps, compulsory requisition of private beds) within 30–90 days, and labour strikes or wage inflation driving agency costs +15–30% over six months. Immediate risks (days–weeks) are operational (ambulance handovers); medium (weeks–months) are earnings misses from higher OPEX; long-term (quarters) include regulatory intervention or capital allocation to NHS reducing private volumes.

Trade implications: Favor short-dated, directional exposure to diagnostics and private acute care and selective longs in staffing firms; use 1–3 month call spreads to capture winter upside while capping premium. Consider relative-value: long large-cap, diversified private operators (HCA, RHC) vs short single-market small UK private operators (SPI.L) where regulatory risk is concentrated.

Contrarian angles: Consensus assumes only transitory demand; market may underprice multi-quarter tailwind from elective backlog (waiting lists >7M). Conversely, underappreciated wage inflation and government intervention could compress private margins — so size positions small (1–2% portfolio each) and use option structures to asymmetrically capture upside.

Key Decisions for Investors

• Establish a 1.5–2.0% long position in HCA Healthcare (HCA) with a 3–6 month horizon; add another 0.5% if England flu hospitalisations exceed 4,000/week or ambulance handover delays widen >10% week-over-week.
• Purchase 3-month call spreads on diagnostics: 1.0% notional split between Abbott (ABT) and Roche (RHHBY) (buy ATM call, sell 20–25% OTM) to target 15–30% upside if winter virus demand persists; take profits or roll down if hospitalisations drop >20% WoW.
• Put on a pair trade: long 1.0–1.5% Amn Healthcare (AMN) vs short 1.0–1.5% Spire Healthcare (SPI.L) for 6 months — staffing firms monetise temp demand while smaller UK operators face concentrated regulatory and margin risk; reassess at 3 months or sooner if UK Dept. of Health announces intervention.
• Allocate 0.5% to a gold ETF (GLD) or buy 3–6 month protective puts on UK sovereign exposure if UK fiscal/news risk rises; exit hedge if NHS pressure indicators (bed occupancy, waiting list change) improve by >30% over a month.